Chromogenex Receives FDA Clearance for Circumferential Reduction for i-Lipo Body Contouring System
Newly introduced to U.S. market, successful system is leading option for physicians treating fat reduction non-surgically.
NEW YORK, NY – Chromogenex announced today that they have received FDA approval to market the i-Lipo low-level laser diode device for circumferential reduction of the waist. i-Lipo is the first direct skin contact laser device designed for fat reduction and body contouring to receive FDA approval for circumference reduction. Based on results from a recent double-blind, placebo-controlled, randomized study of 34 volunteers, the FDA found that over 70% of participants experienced significant inch loss, thus validating the use of i-Lipo to target specifically chosen anatomical areas for fat reduction. The results represented more than double the percentage difference for meeting significant results as defined by the FDA.
“This study supports previous studies completed in France and the UK and from results experienced by current i-Lipo devices already placed in over 1000 commercial clinics worldwide,” stated Peter McGuinness, CEO of Chromogenex Technologies LTD. “This result from the FDA is extremely statistically significant and gives confidence of 99.99% that a participant undertaking i-Lipo will achieve a greater circumference reduction than a participant undertaking exercise alone in a three to four week period.”
The FDA cleared i-Lipo laser weight loss technology has been thoroughly researched in several clinical studies. Read more here >> Clinical Research
Specials & Updates